ANMAT — the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica — is Argentina’s federal health authority and the first gate for any clinical trial in the country. Its clinical trial pathway is well-defined but layered with provincial requirements that catch sponsors who plan only for the federal filing. This guide is the exact operating map bioaccess® uses on ANMAT submissions in 2026.
ANMAT’s legal basis
- Disposición 6677/2010 — the core Good Clinical Practice framework for drug trials.
- Ley 26.529 (Patient Rights Act) — governs informed consent, patient rights, and confidentiality.
- Disposición 4457/2006 and its 2019 update — the medical device clinical investigation pathway.
- Disposición 969/1997 and successor updates — GMP and manufacturing evidence requirements.
Product-class matrix
| Product | Pathway | Typical ANMAT timeline |
|---|---|---|
| Drug studies (small molecule) | Disposición 6677 CTA | 70–95 business days |
| Medical devices (Class I–IV) | Disposición 4457 investigation authorization | 80–110 business days |
| Biologics / biosimilars | ANMAT biologics unit + CTA | 100–140 business days |
| Advanced therapies (ATMPs) | Dedicated ATMP pathway (post-2023) | 140–180 business days |
The federal + provincial dual-track
ANMAT approval is federal, but Argentina’s constitution reserves health regulation to the provinces. In practice this means every site outside CABA (Ciudad Autónoma de Buenos Aires) requires provincial authorization on top of ANMAT. The three provinces sponsors run into most often:
- Buenos Aires Province — Ministerio de Salud Provincial, adds 30–60 days.
- Córdoba — COEIS (Comité de Ética en Investigaciones en Salud) provincial + ministerial track, adds 40–70 days.
- Mendoza — Departamento de Bioética provincial oversight, adds 30–50 days.
Filing federal (ANMAT) and provincial dossiers in parallel is the only way to compress this. Filing them sequentially adds 2–3 months to time-to-FPI.
Dossier requirements
- Protocol in Spanish (executive summary + full technical document).
- Investigator’s Brochure, current version dated within 12 months.
- IMPD or device technical file (ISO 14155 + ISO 13485 for devices).
- GMP certificate for the manufacturing site (PIC/S, FDA, EMA, ANVISA accepted).
- Sponsor local legal representation — mandatory Argentine entity or resident-appointed representative.
- Local clinical trial insurance — must be issued by an Argentine-authorized carrier; foreign policies not accepted without local endorsement.
- Informed consent form in Spanish, tailored to each site’s local ethics committee.
- PI credentials — Matrícula Nacional or provincial medical registration, GCP training evidence.
- CEI (Comité de Ética en Investigación) registration certificates for each site’s ethics committee.
- Budget disclosure and financial arrangements.
- Contracts — CTA with sites, service agreements with CRO.
CEI registration and parallel review
Every CEI in Argentina must be registered with ANMAT and, where applicable, with the provincial health ministry. Not every hospital committee is ANMAT-registered — verify before selecting a site. Independent (non-institutional) CEIs are permitted but face higher scrutiny.
CEI review typically runs 30–50 days for the first pass and 15–25 days for a re-review. Filing CEI review in parallel with ANMAT is standard practice — the federal authority does not require CEI approval to open evaluation, only to authorize enrollment.
Realistic timeline
- Weeks 1–3: Dossier assembly, translations, legal rep and insurance binding.
- Week 3–4: Parallel filing — ANMAT federal + provincial + CEI.
- Weeks 5–16: ANMAT evaluation and provincial review; CEI first-pass review closes in this window.
- Weeks 14–18: Approvals received; import permits filed (ANMAT + Aduana).
- Weeks 18–22: Import cleared, SIV, first-patient enrollment.
Median: 5–5.5 months signed CTA → FPI for a Buenos Aires-only study; add 1–2 months for multi-province studies.
Import permits for IMP and IMD
Investigational product import is a two-step process: ANMAT issues the import authorization tied to the approved CTA, then Aduana (customs) processes the physical entry. Total import cycle: 15–30 days. Common failure mode: expired ANMAT authorization at Aduana — the ANMAT permit typically has a 90-day validity window, and Aduana will reject anything expired.
SAE and periodic safety reporting
- Fatal or life-threatening SAEs: 7 calendar days to ANMAT.
- Non-fatal serious SAEs: 15 calendar days.
- DSUR (Development Safety Update Report): Annual, aligned with international harmonization.
- Line listings: Provided at ANMAT request, typically quarterly for high-risk studies.
How bioaccess® executes ANMAT studies
bioaccess®’s Argentina operating model runs on a Buenos Aires + Rosario site network with two provincial dossiers filed in parallel. Median time to FPI on our last six ANMAT-authorized studies: 5.1 months. Global Trial Accelerators™ coordinates ANMAT filings alongside INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), and MINSA (Panama) under one accountable operating team.
For a scoped ANMAT feasibility call, contact bioaccess®.
Leave a Reply